Molecular Health
Molecular Health is a Heidelberg-based AI biomedical data intelligence company that operates the Dataome knowledge platform and MH Guide variant annotation software to serve pharmaceutical, biotech, and research laboratory customers with drug development and clinical genomics analytics.
- Company typePrivate
- Founded2014
- HeadquartersHeidelberg, Germany
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Molecular Health does
Molecular Health GmbH, founded in 2014 and headquartered in Heidelberg, Germany with a wholly-owned U.S. subsidiary (Molecular Health Inc.), develops AI-driven biomedical data intelligence software for pharmaceutical, biotechnology, and research laboratory customers. Its core technology platform, Dataome Technology, uses proprietary AI/ML text-mining combined with expert curation to structure and integrate molecular, biomedical, and drug-related data into a proprietary knowledgebase covering the human molecular landscape. On top of this platform the company offers two product lines: MH Guide / MH Guide CAS, variant annotation and reporting software for genetic and molecular tumor data (with sub-modules including MH Guide/BRCA for PARP inhibitor variant interpretation and MH Guide/Mendel for hereditary disease genes); and AI Pharma Solutions, a fee-for-service offering for indication finding, biomarker discovery, target identification, trial design and endpoint optimization, and drug safety prediction via the MH Effect and MH Predict technologies.
The company operates an enterprise field sales motion targeting pharma/biotech and research laboratories, with dedicated customer success teams in Germany and the U.S. and contact-based pricing (no published tiers). Distribution is augmented by strategic channel partnerships, notably a global multi-year agreement with Integrated DNA Technologies (IDT, May 2024) pairing MH Guide with IDT's Archer NGS assay platform, and a strategic collaboration with Axxam S.p.A. (June 2025) pairing Dataome insights with biological validation for drug target discovery. Molecular Health is privately held by its founders (CEO Dr. Friedrich von Bohlen und Halbach; CTO Dr. Stephan Brock) with no disclosed external funding rounds or parent company, operates under GDPR-compliant data practices, and maintains an active scientific publication record (18 articles spanning 2016-2026).
Molecular Health firmographics
Firmographics- Name
- Molecular Health
- Legal name
- Molecular Health GmbH
- Website
- https://molecularhealth.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Molecular Health is a Heidelberg-based AI biomedical data intelligence company that operates the Dataome knowledge platform and MH Guide variant annotation software to serve pharmaceutical, biotech, and research laboratory customers with drug development and clinical genomics analytics.
- Ownership category
- akta.pro rank
Molecular Health industry classification
Industry- Product category
- Clinical Genomics and Bioinformatics Software
- NAICS
- Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
Keywords
Where Molecular Health is headquartered
LocationHeadquarters
- HQ city
- Heidelberg
- HQ country
- Germany
- HQ region
- Europe
Offices4 records
Markets served
Molecular Health business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Software Solutions for Research: Software licensing and subscription services for variant annotation, reporting, and analysis tools used by research laboratories and pharmaceutical companies. Includes MH Guide CAS for genetic data annotation.
- AI Pharma Solutions Services: Fee-for-service analytical projects using Dataome Technology for indication finding, biomarker discovery, target identification, trial design, endpoint optimization, and safety prediction.
- Integrated Software Partnerships: Revenue through partnership arrangements that integrate Molecular Health's software with partner platforms (e.g., IDT's NGS workflow), extending distribution reach.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Molecular Health product offering
Product offeringCore offering
Molecular Health develops and sells AI-powered software that transforms biomedical and molecular data into actionable insights for drug development and clinical genomics. Its primary products are MH Guide (a variant annotation and clinical reporting software for genetic and tumor data) and the Dataome biomedical knowledge base, complemented by AI Pharma Solutions services that apply these capabilities to indication finding, biomarker discovery, target identification, trial design optimization, and drug safety prediction for pharmaceutical and research laboratory customers.
Product overview
Molecular Health offers a platform-plus-modules architecture centered on Dataome Technology and MH Guide. Dataome is the core AI-powered biomedical knowledge base that integrates and contextualizes molecular, biomedical, and drug-related data. MH Guide is the primary clinical software for annotating genetic variants with therapy associations and biomarkers. These are supplemented by specialized modules including MH Guide/BRCA for BRCA variant interpretation, MH Guide/Mendel for hereditary disease genes, MH Order Portal for case management, and MH VCF Adapter Suite and MH Connector for NGS workflow integration. The AI Pharma Solutions product line leverages Dataome for pharma/biotech clients requiring indication finding, biomarker identification, target identification, trial design optimization, and drug safety prediction via MH Effect technology.
Differentiator
Problem solved
Functional benefit
Brands
- MH Guide CAS: Case Annotation Solution for annotating genetic and molecular tumor alteration data with published therapy associations, biomarkers, and recruiting clinical trials for research guidance.
- Dataome
- AI Pharma Solutions
Products and services
- MH Guide / MH Guide CAS (Case Annotation Solution)
Quantifiable outcome
- Provides tertiary analysis for NGS data, maximizing lab efficiency and streamlining genomics workflows
Companies that use Molecular Health
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Molecular Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability6 records
Feature6 records
Molecular Health partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Axxam S.p.A.coreStrategic collaboration pairing data-driven clinical-molecular insights with biological validation to identify relevant drug targets and confirm leads for biopharmaceutical companies. Combines Molecular Health's Dataome Technology with Axxam's integrated early discovery services capabilities.
- Integrated DNA Technologies (IDT)coreGlobal multi-year agreement pairing IDT's Archer NGS research assay platform with Molecular Health's variant annotation and reporting software. Equips molecular researchers with tertiary analysis for NGS data, maximizing lab efficiency and streamlining genomics data workflows. Extends access to research customers through IDT's nationwide (U.S.) footprint and global presence. Collaboration enables high-quality, end-to-end integration plus deep understanding of sequencing data for cancer discoveries.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Molecular Health competitors and assessment
Company assessmentDirect peers
- SOPHiA Genetics: SOPHiA Genetics provides AI-powered variant annotation and interpretation for clinical and research genomics. Both companies offer tertiary NGS analysis, biomarker annotation, and clinical trial matching for pharma/research customers, directly competing in variant interpretation.
- Fabric Genomics: Fabric Genomics specializes in NGS variant interpretation and clinical decision support for genomic medicine. Directly comparable to Molecular Health's MH Guide and MH Guide CAS for variant annotation, reporting, and clinical research workflows.
- Congenica: Congenica provides clinical genomics interpretation software for rare disease and hereditary cancer variants. Comparable use cases to Molecular Health's MH Guide/Mendel and MH Guide/BRCA modules for hereditary disease gene interpretation.
- Golden Helix: Golden Helix offers variant annotation and clinical reporting software for NGS workflows. Competes in similar territory as Molecular Health's MH Guide CAS for research laboratories and clinical genomics reporting.
- Schrödinger: Schrödinger provides a computational platform for drug discovery including target identification, molecular design, and predictive modeling. Comparable to Molecular Health's AI Pharma Solutions and Dataome Technology for pharma/biotech target identification and indication finding.
- Recursion Pharmaceuticals: Recursion is an AI-driven drug discovery platform combining high-throughput biology with machine learning. Overlaps with Molecular Health's AI Pharma Solutions for target identification, indication finding, and predictive analytics in pharma/biotech.
- Exscientia: Exscientia applies AI to drug design and target discovery with patient-derived data. Comparable to Molecular Health's predictive analytics capabilities for drug development, indication finding, and safety prediction.
Broad incumbents
- QIAGEN: QIAGEN is a major life sciences tools and bioinformatics provider offering QIAseq and Ingenuity variant analysis tools. Broader portfolio than Molecular Health but significant overlap in NGS variant interpretation and clinical genomics workflows.
- Tempus AI: Tempus AI is a data-driven precision medicine company offering AI-enabled diagnostics, biomarker discovery, and clinical trial matching. Broader portfolio but overlapping use cases in biomarker identification, trial matching, and pharma data services.
- Illumina: Illumina is the dominant NGS platform provider with adjacent bioinformatics offerings through BaseSpace and various partnerships. As a broader incumbent, Illumina's ecosystem competes with Molecular Health's IDT partnership for NGS workflow ownership.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Molecular Health social profiles
Digital presenceMolecular Health compliance and trust
Trust signalCompliance1 record
Molecular Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Molecular Health leadership team
Management profileNumber of profiles
Profiles4 records
Molecular Health subsidiaries and ownership
Company hierarchySubsidiaries1 record
Molecular Health funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Molecular Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Molecular Health
What does Molecular Health do?
Molecular Health develops and sells AI-powered software that transforms biomedical and molecular data into actionable insights for drug development and clinical genomics. Its primary products are MH Guide (a variant annotation and clinical reporting software for genetic and tumor data) and the Dataome biomedical knowledge base, complemented by AI Pharma Solutions services that apply these capabilities to indication finding, biomarker discovery, target identification, trial design optimization, and drug safety prediction for pharmaceutical and research laboratory customers.
Is Molecular Health a public or private company?
Molecular Health is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Molecular Health founded?
Molecular Health was founded in 2014. It employs 101 to 250 people.
Where is Molecular Health based?
Molecular Health is headquartered in Heidelberg, Germany, in the Europe region.
How does Molecular Health make money?
Three revenue lines are on record. Software Solutions for Research is the primary driver. The others are AI Pharma Solutions Services and integrated Software Partnerships.
Who are Molecular Health's main competitors?
Direct peers on record are SOPHiA Genetics, Fabric Genomics, Congenica, Golden Helix, Schrödinger, Recursion Pharmaceuticals and Exscientia. Broad incumbents are QIAGEN, Tempus AI and Illumina.
Does Molecular Health have an API?
No public API is recorded for Molecular Health.
What industry is Molecular Health in?
Molecular Health's product category is Clinical Genomics and Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 5132.